Fortitude Biomedicines Announces Oral Presentation of FTB — 918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026
For best results when printing this announcement, please click on link below: Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026 FTB-918 is a first-in-class, dual-targeting antibody fusion engineered to simultaneously deplete pathogenic T c